Gene targeting in ischemic heart disease and failure: translational and clinical studies.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Biochemical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bcp.2012.08.018PMID 22935384PMCID PMC3575101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade

  2012cited by this paper
• Instructive Nanofiber Scaffolds with VEGF Create a Microenvironment for Arteriogenesis and Cardiac Repair

  2012cited by this paper
• Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure

  2011cited by this paper
• S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes.

  2011cited by this paper
• The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

  2011cited by this paper
• Introduction to viral vectors.

  2011cited by this paper
• G protein-coupled receptor kinases in normal and failing myocardium.

  2011cited by this paper
• Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.

  2011cited by this paper
• Transposon-based vector systems for gene therapy clinical trials: challenges and considerations.

  2011cited by this paper
• GRK2 as a novel gene therapy target in heart failure.

  2011cited by this paper
• Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model

  2011cited by this paper
• Novel Hyperactive Transposons for Genetic Modification of Induced Pluripotent and Adult Stem Cells: A Nonviral Paradigm for Coaxed Differentiation

  2010cited by this paper
• S100A1: A Multifaceted Therapeutic Target in Cardiovascular Disease

  2010cited by this paper
• piggyBac Transposon-mediated Long-term Gene Expression in Mice

  2010cited by this paper
• In Vivo Electroporation Mediated Gene Delivery to the Beating Heart

  2010cited by this paper
• A transposon and transposase system for human application.

  2010cited by this paper
• Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

  2009cited by this paper
• Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells.

  2009cited by this paper
• VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.

  2009cited by this paper
• Transposon-mediated genome manipulation in vertebrates

  2009cited by this paper
• Applying a “Double‐Feature” Promoter to Identify Cardiomyocytes Differentiated from Human Embryonic Stem Cells Following Transposon‐Based Gene Delivery

  2009cited by this paper
• Nonviral Gene Delivery: Principle, Limitations, and Recent Progress

  2009cited by this paper
• Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.

  2008cited by this paper
• Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.

  2008cited by this paper
• Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals

  2008cited by this paper
• Progress reported in two studies of clinical gene transfer into the retina.

  2008cited by this paper
• Recombinant adeno-associated virus transduction and integration.

  2008cited by this paper
• CD4+CD25− T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model1

  2008cited by this paper
• Cardiovascular gene therapy: current status and therapeutic potential

  2007cited by this paper
• Neointimal formation following drug-eluting stents: physiology, timeline, and the influence of drug delivery systems.

  2007cited by this paper
• Gene therapy in the treatment of heart failure.

  2007cited by this paper
• Injection of adeno-associated viral vector encoding vascular endothelial growth factor gene in infarcted swine myocardium: MR measurements of left ventricular function and strain.

  2007cited by this paper
• New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy.

  2007cited by this paper
• Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals.

  2007cited by this paper
• Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials.

  2007cited by this paper
• Gene therapy: targeting the myocardium

  2007cited by this paper
• Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance.

  2006influential reference
• Sleeping Beauty‐mediated eNOS gene therapy attenuates monocrotaline‐induced pulmonary hypertension in rats

  2006cited by this paper
• Viral vectors for gene delivery in tissue engineering.

  2006cited by this paper
• Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease.

  2006cited by this paper
• Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation.

  2006influential reference
• Adeno-Associated Virus-Mediated Transduction of VEGF165 Improves Cardiac Tissue Viability and Functional Recovery After Permanent Coronary Occlusion in Conscious Dogs

  2006cited by this paper
• Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs.

  2006cited by this paper
• Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment

  2006cited by this paper
• Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia.

  2006cited by this paper
• Gene therapy of fibroproliferative vasculopathies: current ideas in molecular mechanisms and biomedical technology.

  2006cited by this paper
• The mechanism of naked DNA uptake and expression.

  2005cited by this paper
• Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.

  2005influential reference
• Adeno-associated virus: from defective virus to effective vector

  2005cited by this paper
• A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia

  2005cited by this paper
• A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.

  2005cited by this paper
• Adenoviral Gene Transfer of FGF-5 to Hibernating Myocardium Improves Function and Stimulates Myocytes to Hypertrophy and Reenter the Cell Cycle

  2005cited by this paper
• Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery.

  2004cited by this paper
• Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling.

  2004cited by this paper
• Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor-D Induces Transmural Angiogenesis in Porcine Heart

  2004cited by this paper
• Integration of adeno-associated virus (AAV) and recombinant AAV vectors.

  2004cited by this paper
• Intracoronary Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function in Heart Failure

  2004cited by this paper
• Endothelial targeting of the Sleeping Beauty transposon within lung.

  2004cited by this paper
• Increased Regional Function and Perfusion After Intracoronary Delivery of Adenovirus Encoding Fibroblast Growth Factor 4: Report of Preclinical Data

  2004cited by this paper
• Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT)

  2003influential reference
• One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients.

  2003cited by this paper
• A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina.

  2003influential reference
• Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo

  2002cited by this paper
• Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging.

  2002cited by this paper
• Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia

  2002cited by this paper
• Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris

  2002influential reference
• Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.

  2001cited by this paper
• Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia.

  2001influential reference
• Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia

  2001cited by this paper
• Effects of intramyocardial injection of phVEGF‐A165 as sole therapy in patients with refractory coronary artery disease – 12‐month follow‐up: Angiogenic gene therapy

  2001cited by this paper
• Catheter-Mediated Vascular Endothelial Growth Factor Gene Transfer to Human Coronary Arteries after Angioplasty

  2000influential reference
• Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins

  2000cited by this paper
• Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction.

  2000cited by this paper
• Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium.

  2000cited by this paper
• Intramyocardial Gene Therapy with Naked DNA Encoding Vascular Endothelial Growth Factor Improves Collateral Flow to Ischemic Myocardium

  1999cited by this paper
• Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping.

  1999influential reference
• Gene Therapy Vectors Based on Adeno-Associated Virus Type 1

  1999cited by this paper
• Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

  1999cited by this paper
• Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.

  1999cited by this paper
• Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

  1999cited by this paper
• Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

  1998influential reference
• Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.

  1998cited by this paper
• Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery

  1998cited by this paper
• Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.

  1997cited by this paper
• Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector.

  1996cited by this paper
• Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart

  1996cited by this paper
• Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

  1996cited by this paper
• The Fate of Plasmid DNA After Intravenous Injection in Mice: Involvement of Scavenger Receptors in Its Hepatic Uptake

  1995cited by this paper
• The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.

  1994cited by this paper
• Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors.

  1994cited by this paper
• Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis.

  1994cited by this paper
• Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

  1987cited by this paper
• Adenovirus-Associated Defective Virus Particles

  1965cited by this paper

• Cardiac rehabilitation in porcine models: Advances in therapeutic strategies for ischemic heart disease

  2025cites this paper
• Intracellular delivery of a phospholamban-targeting aptamer using cardiomyocyte-internalizing aptamers.

  2024cites this paper
• Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.

  2024cites this paper
• VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium

  2021cites this paper
• Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction

  2020cites this paper
• Gene and cell therapy approaches for the prevention and treatment of ventricular arrhythmias

  2020cites this paper
• Toll Like Receptor 2 Genotypes and Intra-Coronary Stent Restenosis

  2019cites this paper
• Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

  2017cites this paper
• A Swine Model of Percutaneous Intracoronary Ethanol Induced Acute Myocardial Infarction and Ischemic Mitral Regurgitation

  2017cites this paper
• G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis

  2016cites this paper
• Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.

  2016cites this paper
• Gene Therapy in Cardiovascular Disease

  2015cites this paper
• [Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I].

  2014cites this paper
• A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile function in cardiomyocytes.

  2014cites this paper
• Gene therapy for in-stent restenosis: Targets and delivery system

  2014cites this paper
• Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle

  2013cites this paper